Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Lipigon Pharmaceuticals

0.089

 

SEK

 

+1.14 %

Less than 1K followers

LPGO

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
Compare
+1.14%
-12.21%
+4.76%
+0.04%
-33.96%
-60.4%
-94.56%
-
-98.44%

Lipigon Pharmaceuticals operates in the pharmaceutical industry. The company specializes in the research and development of various drug candidates. The product portfolio is broad and includes drugs for rare diseases. These are mainly treatments for diseases caused by disorders in the body's handling of fats. In addition to the main business, service and associated ancillary services are also offered. Lipigon Pharmaceuticals operates worldwide, with the largest presence in the Nordic market.

Read more
Market cap
49.94M SEK
Turnover
167.11K SEK
Revenue
10.29M
EBIT %
-248.59 %
P/E
-
Dividend yield-%
-
Financial calendar
26.6
2025

General meeting '25

26.8
2025

Interim report Q2'25

20.11
2025

Interim report Q3'25

All
Press releases
ShowingAll content types
Press release5/27/2025, 6:36 AM

Redeye: Lipigon Q1 2025 - 64.5% Subscription Rate in the Rights Issue

Lipigon Pharmaceuticals
Press release3/31/2025, 6:25 AM

Redeye: Lipigon Q4 2024 - Rights issue funds 2025

Lipigon Pharmaceuticals
Regulatory press release3/20/2025, 11:15 AM

Lipigon Pharmaceuticals' commercial partner announces positive results from Phase I clinical trial with Lipisense

Lipigon Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release11/21/2024, 1:12 PM

Redeye: Lipigon Q3 2024 - First Patient Recruited

Lipigon Pharmaceuticals
Regulatory press release11/21/2024, 9:00 AM

Första patienten doserad i Lipigon Pharmaceuticals kliniska fas II-studie med Lipisense®

Lipigon Pharmaceuticals
Press release9/18/2024, 10:51 AM

Lipigon's development partner Leaderna Therapeutics reports last person treated in ongoing Phase 1 study with Lipisense®

Lipigon Pharmaceuticals
Press release8/28/2024, 5:43 AM

Redeye: Lipigon Q2 2024 - Marea Launched

Lipigon Pharmaceuticals
Regulatory press release7/9/2024, 12:00 PM

Lipigon Receives Milestone Payment of USD 1 Million from Leaderna for Approval of Phase I Bridging Study

Lipigon Pharmaceuticals
Press release6/20/2024, 6:30 AM

New Publication: The ANGPTL4 Protein May Reduce the Risk of Cardiovascular Disease and Diabetes

Lipigon Pharmaceuticals
Press release5/29/2024, 6:03 AM

Redeye: Lipigon Q1 2024 - Phase II Underway

Lipigon Pharmaceuticals
Press release5/15/2024, 6:28 AM

Lipigon and Leaderna Collaboration on Lipisense® Shows Good Progress

Lipigon Pharmaceuticals
Regulatory press release5/14/2024, 5:53 AM

Lipigon collaborates with University of Washington on lung damage project

Lipigon Pharmaceuticals
Press release2/23/2024, 7:08 AM

Redeye: Lipigon Q4 2023 - Phase II study approved

Lipigon Pharmaceuticals
Press release2/7/2024, 3:00 PM

The Swedish Medical Products Agency approves Lipigon's phase II study with Lipisense®

Lipigon Pharmaceuticals
Press release12/12/2023, 9:11 AM

Lipisense® progressing to Phase II - what comes next?

Lipigon Pharmaceuticals
Press release11/28/2023, 7:13 AM

Lipigon presents Lipisense® at Global CVCT Forum 2023

Lipigon Pharmaceuticals
Press release11/24/2023, 7:16 AM

Redeye: Lipigon Q3 2023 - Stage set for Phase II

Lipigon Pharmaceuticals
Regulatory press release11/23/2023, 2:45 PM

Lipigon reports a statistically confirmed reduction of target protein ANGPTL4 after repeated treatment with Lipisense®

Lipigon Pharmaceuticals
Regulatory press release11/13/2023, 7:28 AM

Lipigon applies for clinical trial Phase II for Lipisense®

Lipigon Pharmaceuticals
Regulatory press release10/10/2023, 1:29 PM

Lipigon secures US patent for treatment of cardiometabolic disease

Lipigon Pharmaceuticals
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team